Covered recipient · General Payments record
HARRY E SARLES
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$46,210.39
151 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $37,700.00 | 13 |
| Travel and Lodging | $4,457.18 | 17 |
| Food and Beverage | $4,053.21 | 121 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | $44,492.20 | 63 |
| ABBVIE INC. | $770.17 | 45 |
| Takeda Pharmaceuticals U.S.A., Inc. | $141.19 | 11 |
| Janssen Scientific Affairs, LLC | $140.49 | 1 |
| GENZYME CORPORATION | $131.70 | 5 |
| Janssen Biotech, Inc. | $130.38 | 8 |
| PFIZER INC. | $74.00 | 5 |
| SHIELD THERAPEUTICS INC | $73.10 | 1 |
| Ferring Pharmaceuticals Inc. | $59.31 | 3 |
| Ardelyx, Inc. | $44.89 | 2 |
| IRONWOOD PHARMACEUTICALS, INC | $26.11 | 1 |
| Ipsen Biopharmaceuticals, Inc | $25.15 | 1 |
| Intercept Pharmaceuticals, Inc. | $24.20 | 1 |
| Teva Pharmaceuticals USA, Inc. | $24.17 | 1 |
| Merck Sharp & Dohme LLC | $22.28 | 1 |
| Celgene Corporation | $17.49 | 1 |
| VIVUS LLC | $13.56 | 1 |
Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HARRY E SARLES
NPI 1861451395 · CMS profile ID 311621
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
ROCKWALL, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HARRY E SARLES, NPI 1861451395, CMS profile ID 311621. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). HARRY E SARLES, NPI 1861451395, CMS profile ID 311621. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- HARRY E SARLES, NPI 1861451395, CMS profile ID 311621, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 151 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1861451395?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
151 matching records · $46,210.39 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 151.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $5.47 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137668640 | CMS |
| ABBVIE INC. | $15.13 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021342 | CMS |
| ABBVIE INC. | $8.68 | 08/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021340 | CMS |
| ABBVIE INC. | $21.77 | 08/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021338 | CMS |
| GENZYME CORPORATION | $24.02 | 08/13/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139902990 | CMS |
| Phathom Pharmaceuticals, Inc. | $325.00 | 07/31/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120766 | CMS |
| ABBVIE INC. | $23.70 | 07/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021336 | CMS |
| Phathom Pharmaceuticals, Inc. | $29.30 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120756 | CMS |
| Phathom Pharmaceuticals, Inc. | $29.30 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120758 | CMS |
| Phathom Pharmaceuticals, Inc. | $55.61 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120760 | CMS |
| Phathom Pharmaceuticals, Inc. | $47.87 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120762 | CMS |
| Phathom Pharmaceuticals, Inc. | $35.23 | 07/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120764 | CMS |
| Phathom Pharmaceuticals, Inc. | $346.09 | 07/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120750 | CMS |
| Phathom Pharmaceuticals, Inc. | $571.95 | 07/26/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120752 | CMS |
| Phathom Pharmaceuticals, Inc. | $135.00 | 07/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120754 | CMS |
| ABBVIE INC. | $16.89 | 07/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021334 | CMS |
| Phathom Pharmaceuticals, Inc. | $3,500.00 | 07/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120748 | CMS |
| Phathom Pharmaceuticals, Inc. | $3,500.00 | 07/17/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120746 | CMS |
| ABBVIE INC. | $14.20 | 07/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021332 | CMS |
| Phathom Pharmaceuticals, Inc. | $184.10 | 07/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120738 | CMS |
| Phathom Pharmaceuticals, Inc. | $438.21 | 07/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120740 | CMS |
| Phathom Pharmaceuticals, Inc. | $119.90 | 07/11/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120742 | CMS |
| Phathom Pharmaceuticals, Inc. | $292.00 | 07/11/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120744 | CMS |
| ABBVIE INC. | $24.45 | 07/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021330 | CMS |
| GENZYME CORPORATION | $19.40 | 06/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139902970 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $5.40 | 06/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137668638 | CMS |
| ABBVIE INC. | $15.18 | 06/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021328 | CMS |
| ABBVIE INC. | $8.87 | 06/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021326 | CMS |
| ABBVIE INC. | $13.31 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021324 | CMS |
| Ardelyx, Inc. | $17.65 | 06/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146705947 | CMS |
| Celgene Corporation | $17.49 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101110294 | CMS |
| Janssen Scientific Affairs, LLC | $140.49 | 06/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078860525 | CMS |
| Ferring Pharmaceuticals Inc. | $18.78 | 06/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137508150 | CMS |
| SHIELD THERAPEUTICS INC | $73.10 | 06/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150134087 | CMS |
| ABBVIE INC. | $20.72 | 06/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021322 | CMS |
| Phathom Pharmaceuticals, Inc. | $16.48 | 06/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120736 | CMS |
| GENZYME CORPORATION | $24.99 | 05/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139902956 | CMS |
| Phathom Pharmaceuticals, Inc. | $80.40 | 05/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120732 | CMS |
| Phathom Pharmaceuticals, Inc. | $46.90 | 05/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120734 | CMS |
| Ferring Pharmaceuticals Inc. | $18.77 | 05/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137508146 | CMS |
| GENZYME CORPORATION | $25.45 | 05/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139902964 | CMS |
| ABBVIE INC. | $13.81 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021320 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $6.47 | 05/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137668636 | CMS |
| ABBVIE INC. | $24.21 | 05/15/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021318 | CMS |
| ABBVIE INC. | $16.50 | 05/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021316 | CMS |
| Phathom Pharmaceuticals, Inc. | $2,500.00 | 05/08/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120730 | CMS |
| ABBVIE INC. | $8.37 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021312 | CMS |
| ABBVIE INC. | $13.78 | 05/02/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1106021314 | CMS |
| Phathom Pharmaceuticals, Inc. | $2,500.00 | 05/01/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120728 | CMS |
| Phathom Pharmaceuticals, Inc. | $52.55 | 04/30/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1151120726 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $134.26 | 2 |
| PY2025 | Principal investigator | $225,854.87 | 68 |
| PY2024 | Principal investigator | $291,590.16 | 32 |
| PY2023 | Recipient | $20.09 | 1 |
| PY2023 | Principal investigator | $278,289.44 | 38 |
| PY2022 | Recipient | $845.67 | 1 |
| PY2022 | Principal investigator | $298,537.94 | 65 |
| PY2021 | Recipient | $11,777.72 | 6 |
| PY2021 | Principal investigator | $506,702.67 | 85 |
| PY2020 | Recipient | $171.90 | 1 |
| PY2020 | Principal investigator | $1,100,186.30 | 202 |
| PY2019 | Recipient | $4,459.85 | 15 |
| PY2019 | Principal investigator | $1,314,813.06 | 219 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
70 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,626.40 | 12/26/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672814 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $903.00 | 12/19/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672816 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $903.00 | 12/19/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672818 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,183.20 | 12/19/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672820 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,379.00 | 12/19/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211663014 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 12/17/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672828 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 12/17/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672830 |
| Principal investigator 1 | ABBVIE INC. | $9,039.80 | 12/16/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202530602 |
| Principal investigator 1 | ABBVIE INC. | $1,932.15 | 12/04/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202527820 |
| Principal investigator 1 | Genentech, Inc. | $2,743.00 | 11/25/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211663460 |
| Principal investigator 1 | ABBVIE INC. | $736.70 | 11/20/2025 | Non-covered Recipient Entity DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202525002 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24,259.20 | 10/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672812 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $69.96 | 10/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672822 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 10/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672824 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 10/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672826 |
| Recipient | Eli Lilly and Company | $64.26 | 10/20/2025 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187876339 |
| Principal investigator 1 | ABBVIE INC. | $3,100.00 | 10/09/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202514755 |
| Principal investigator 1 | Genentech, Inc. | $2,540.00 | 10/09/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211663378 |
| Recipient | Eli Lilly and Company | $70.00 | 09/30/2025 | Covered Recipient Physician | A PHASE 3, MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS LUCENT 3 | No dispute reported | 06/30/2026 | 1187872413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 09/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672806 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 09/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672808 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.00 | 09/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672810 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $7,218.00 | 09/23/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211662933 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $7,276.00 | 09/18/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants, PLLC | A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) | No dispute reported | 06/30/2026 | 1244044792 |
| Principal investigator 1 | ABBVIE INC. | $3,600.00 | 09/10/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202510510 |
| Principal investigator 1 | AstraZeneca UK Limited | $3,900.00 | 09/10/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLANO | A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients with Moderate to Severe Crohns Disease AMALTHEA | No dispute reported | 06/30/2026 | 1185539061 |
| Principal investigator 1 | ABBVIE INC. | $5,100.00 | 09/04/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202509656 |
| Principal investigator 1 | ABBVIE INC. | $3,767.40 | 09/04/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202509658 |
| Principal investigator 1 | ABBVIE INC. | $3,600.00 | 08/26/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202505869 |
| Principal investigator 1 | ABBVIE INC. | $3,600.00 | 08/26/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202505871 |
| Principal investigator 1 | ABBVIE INC. | $7,058.80 | 08/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202503545 |
| Principal investigator 1 | ABBVIE INC. | $1,526.20 | 08/05/2025 | Non-covered Recipient Entity DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202502170 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $6,635.00 | 07/31/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211662962 |
| Principal investigator 1 | ABBVIE INC. | $665.00 | 07/11/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202498110 |
| Principal investigator 1 | ABBVIE INC. | $6,186.25 | 07/02/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202496379 |
| Principal investigator 1 | ABBVIE INC. | $321.30 | 07/02/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202496503 |
| Principal investigator 1 | ABBVIE INC. | $4,971.40 | 07/02/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD) | No dispute reported | 06/30/2026 | 1202496505 |
| Principal investigator 1 | Genentech, Inc. | $7,695.00 | 06/19/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211663083 |
| Principal investigator 1 | ABBVIE INC. | $3,599.40 | 06/12/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202491171 |
| Principal investigator 1 | ABBVIE INC. | $1,181.70 | 06/12/2025 | Non-covered Recipient Entity DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202491175 |
| Principal investigator 1 | ABBVIE INC. | $6,187.50 | 06/12/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202491177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 05/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672796 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 05/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672798 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 05/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672800 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 05/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672802 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 05/27/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672804 |
| Principal investigator 1 | ABBVIE INC. | $3,599.40 | 05/15/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202485181 |
| Principal investigator 1 | ABBVIE INC. | $3,767.40 | 04/03/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202473376 |
| Principal investigator 1 | ABBVIE INC. | $428.00 | 04/03/2025 | Non-covered Recipient Entity DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202473379 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.71 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672780 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672782 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672784 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.00 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672786 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672788 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672790 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672792 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.43 | 03/24/2025 | Non-covered Recipient Entity Digestive Health Associates Of Texas Garland-N Pgb Highway | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220672794 |
| Principal investigator 1 | ABBVIE INC. | $6,925.80 | 03/07/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202459170 |
| Principal investigator 1 | ABBVIE INC. | $3,141.00 | 03/06/2025 | Non-covered Recipient Entity DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202456395 |
| Principal investigator 1 | Genentech, Inc. | $4,940.00 | 02/18/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211663109 |
| Principal investigator 1 | Genentech, Inc. | $16,500.00 | 02/18/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211663213 |
| Principal investigator 1 | ABBVIE INC. | $941.85 | 02/06/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202446757 |
| Principal investigator 1 | ABBVIE INC. | $941.85 | 01/17/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202439856 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 01/17/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE | M21-446 - Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202439859 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $20,671.00 | 01/15/2025 | Non-covered Recipient Entity Texas Digestive Disease Consultants Southlake | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235993301 |
| Principal investigator 1 | ABBVIE INC. | $2,310.00 | 01/14/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202438516 |
| Principal investigator 1 | Celgene Corporation | $12,700.00 | 01/13/2025 | Non-covered Recipient Entity GI Alliance Department Of Clinical Research And Education | A Phase 3, Multi-Center, Multi-National, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects with Active Eosinophilic Esophagitis. | No dispute reported | 06/30/2026 | 1222307037 |
| Principal investigator 1 | ABBVIE INC. | $2,310.00 | 01/09/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | M23-703 - A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202437772 |
| Principal investigator 1 | ABBVIE INC. | $1,481.25 | 01/02/2025 | Non-covered Recipient Entity TEXAS DIGESTIVE DISEASE CONS PLLC | M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202433438 |
| Principal investigator 1 | ABBVIE INC. | $1,306.50 | 01/02/2025 | Non-covered Recipient Entity DIGESTIVE HEALTH ASSOCIATES OF TEXAS PA | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202435890 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2024 | Amount invested | $0.00 | 1 |
| PY2024 | Value of interest | $13,618.93 | 1 |
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $13,618.93 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $855.42 | 1 |
| PY2021 | Amount invested | $725.07 | 1 |
| PY2021 | Value of interest | $906.58 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
4 records · PY2021–2024
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2024 | GastroGPO, LLC | $0.00 | $13,618.93 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1124820230 |
| PY2023 | GastroGPO, LLC | $0.00 | $13,618.93 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1050730605 |
| PY2022 | GastroGPO, LLC | $0.00 | $855.42 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 955001111 |
| PY2021 | GastroGPO, LLC | $725.07 | $906.58 | Common Stock | Physician Covered Recipient | No dispute reported | 06/30/2026 | 854913981 |